Artificial, which develops software to help life science laboratories automate R&D work, raises $21.5M Series A led by Microsoft's M12
Context & Ripple Effects
Artificial's raise slots into a funding line that has run for nearly a decade: software that takes over life-science bench work. London's BenevolentAI set an early benchmark with a $115M round for AI drug discovery, and since then investors have backed successive slices of the same workflow — LabGenius pairing AI with robotic automation for protein discovery, Benchling building the software layer for managing biotech research, and more recently Cradle's $24M Series A for AI-designed proteins.
What is new here is who is writing the check: M12, Microsoft's venture arm, leading Artificial's Series A puts a major cloud vendor's capital directly behind lab-automation tooling. The most recent data point before this was Conceivable Life Sciences' $50M raise to automate embryologists' work, confirming the appetite extends beyond drug discovery into clinical lab functions.
First-order effects
- Artificial gains $21.5M to scale its lab R&D automation software, while M12 adds a life-science automation position to Microsoft's portfolio alongside its cloud business.
- Life-science labs evaluating automation vendors now have a newly capitalized entrant competing against established research-software players like Benchling.
Second-order effects
- Incumbent lab-software providers face pressure to bundle automation and AI capabilities rather than sell research data management alone, as funded rivals like Cradle and LabGenius push further into actual experimental work.
- Corporate venture arms at cloud vendors gain a template: backing lab-automation startups creates demand pull for compute and cloud services into pharmaceutical and biotech customers.
Third-order effects
- If the funding cadence holds — drug discovery, protein engineering, embryology, and now general R&D automation all attracting rounds — the laboratory itself trends toward becoming a software-defined environment, with platform ownership concentrating among whoever controls the orchestration layer.
- Cloud vendors deepening their stakes through vehicles like M12 points toward life-science IT consolidating around a handful of hyperscaler ecosystems rather than independent stacks.
The trend: Venture and corporate capital are steadily converting the physical life-science lab into a software-orchestrated operation, one workflow at a time.